TICKERNOMICS Sign up
Last Update: 2023-12-23 06:05:47
Knight Therapeutics Inc ( GUD.TO ) https://www.gud-knight.com
3.84USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
Canada
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
GUD.TO
0.21%
SPY
30.72%
-7.80%
GUD.TO
SPY
112.82%
-31.14%
GUD.TO
SPY
201.04%
GUD.TO
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
403.25
385.85
0.05
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-75.97
1.63
0.67
2.90
0.00
5.06
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
2.81
49.30
30.74
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.4332
1.77
1.55
0.38
Other Earnings and Cash Flow Stats:
Knight Therapeutics Inc ( GUD.TO ) Net Income TTM ($MM) is -5.43
Knight Therapeutics Inc ( GUD.TO ) Operating Income TTM ($MM) is 2.09
Knight Therapeutics Inc ( GUD.TO ) Owners' Earnings Annual ($MM) is 0.00
Knight Therapeutics Inc ( GUD.TO ) Current Price to Owners' Earnings ratio is 0.00
Knight Therapeutics Inc ( GUD.TO ) EBITDA TTM ($MM) is 67.56
Knight Therapeutics Inc ( GUD.TO ) EBITDA Margin is 30.74%
Capital Allocation:
Knight Therapeutics Inc ( GUD.TO ) has paid 0.00 dividends per share and bought back 10.236919 million shares in the past 12 months
Knight Therapeutics Inc ( GUD.TO ) has increased its debt by 12.346279540284 million USD in the last 12 months
Capital Structure:
Knight Therapeutics Inc ( GUD.TO ) Interest-bearing Debt ($MM) as of last quarter is 60
Knight Therapeutics Inc ( GUD.TO ) Annual Working Capital Investments ($MM) are 2
Knight Therapeutics Inc ( GUD.TO ) Book Value ($MM) as of last quarter is 603
Knight Therapeutics Inc ( GUD.TO ) Debt/Capital as of last quarter is 10%
Other Balance Sheet Stats:
Knight Therapeutics Inc ( GUD.TO ) has 57 million in cash on hand as of last quarter
Knight Therapeutics Inc ( GUD.TO ) has 85 million of liabilities due within 12 months, and long term debt 55 as of last quarter
Knight Therapeutics Inc ( GUD.TO ) has 104 common shares outstanding as of last quarter
Knight Therapeutics Inc ( GUD.TO ) has 0 million USD of preferred stock value
Academic Scores:
Knight Therapeutics Inc ( GUD.TO ) Altman Z-Score is 2.59 as of last quarter
Knight Therapeutics Inc ( GUD.TO ) Piotroski Score is 7.00 as of last quarter
Corporate Governance:
Knight Therapeutics Inc ( GUD.TO ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Knight Therapeutics Inc ( GUD.TO ) for the amount of $ on
31.72% of Knight Therapeutics Inc ( GUD.TO ) is held by insiders, and 10.54% is held by institutions
Knight Therapeutics Inc ( GUD.TO ) went public on 1970-01-01
Other Knight Therapeutics Inc ( GUD.TO ) financial metrics:
FCF:10.70
Unlevered Free Cash Flow:0.00
EPS:0.28
Operating Margin:2.81
Gross Profit Margin:49.30
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:4.79
Beta:0.38
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Knight Therapeutics Inc ( GUD.TO ) :
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.